Carasent (tidligere Apptix)

Hod · oktober 5, 2020, 6:53am

Av hva jeg hører fra vårt lokale legekontor så er pridok favoritten ved neste bytte. Helserespons som da går ut.

TekBot · oktober 9, 2020, 9:06am

Carasent ASA: New share capital registered

Reference is made to previous announcement concerning a completed private placement (the “Private Placement”) in Carasent ASA (“Carasent” or the “Company”). The share capital increase pertaining to the Private Placement is now registered with the Norwegian Register of Business Enterprises (“Foretaksregisteret”).

The new share capital of the Company is NOK 70,361,525.29 divided into 52,823,968 shares at NOK 1.332 per share.
…

Vis børsmeldingen

A total of 12,190,146 new shares are issued, of which 8,126,763 shares, just below 20% of the outstanding share capital of the Company prior to the Private Placement, will be registered on the Company’s ordinary ISIN and will be listed upon issuance. The remaining portion of the new shares to be issued, totaling 4,063,383 shares, will be registered on a separate ISIN and will be unlisted pending approval of a listing prospectus (the “Prospectus”) by the Norwegian Financial Supervisory Authority (the “NFSA”).

Kilde

TekBot · oktober 14, 2020, 11:40am

CARASENT ASA: PRESENTATION OF Q3 2020 FINANCIAL RESULTS

Panopticon · oktober 14, 2020, 3:30pm

I Carasent er vel enhjørninger og regnbuer priset inn nå?

På tide å ta en titt på CSAM Health Group som ble notert forrige fredag

Bra_Britt · oktober 14, 2020, 7:00pm

Dette selskapet er veldig interessant, eier begge

winjard · oktober 15, 2020, 8:18am

Patientsky henter penger for M&A aktivitet etc også. Verdsettes ganske likt som Carasent… Ved første øyekast på regnskapshistorikk ville jeg nok heller eid Carasent til denne prisen, men har ikke satt meg inn i Patientsky enda da lite informasjon er tilgjengelig.

PatientSky Group vurderer rettet emisjon og notering på Merkur

PatientSky Group har engasjert Carnegie og DNB Markets som rådgivere for en rettet emisjon på 500 millioner kroner ved utstedelse av nye aksjer, ifølge en melding torsdag.

Pris per aksje i tilbudet er satt til 10,21 kroner, noe som tilsvarer en egenkapitalverdi før emisjon på ca. 1,2 milliarder kroner.

Selskapet har søkt om notering på Merkur Markets og forventer at første handelsdag vil være 23. oktober 2020.

Provenyet vil brukes til vekstinitiativer, M&A aktivitet, oppskalering av organisasjonen og delvis nedbetaling av eksisterende gjeld, går det frem av meldingen.

Slobo · oktober 16, 2020, 7:04am

Redeye tar opp dekning i Carasent, med kursmål 40 (base case):

Slobo · oktober 16, 2020, 3:01pm

rayman · oktober 16, 2020, 8:12pm

Fantastisk, kjøpt og betalt annonse som er skrevet av aksjonærer… Dagens marked <3

Kaisovski · oktober 16, 2020, 8:16pm

Håhå. Nøff nøff. Grisete.

TekBot · oktober 22, 2020, 6:01am

Carasent ASA: Q3, 2020 Financial Report

TekBot · oktober 22, 2020, 6:29am

Carasent ASA: Presentation for Q3 2020

Hocki · oktober 22, 2020, 6:40am

winjard · november 10, 2020, 9:16am

Pasientsky kjøper Infodoc i avtale verdt 280 millioner

E-helseselskapet Pasientsky skriver i en børsmelding tirsdag at det har inngått en avtale om overtakelse av alle aksjene i Infodoc den Bergen-baserte e-helseleverandøren Infodoc as.

Pasientsky opplyser at verdien på avtalen er omtrent 280 millioner norske kroner, en verdsetting som er basert på en forventning om en omsetning på 57 millioner kroner i 2020.

Transaksjonen er ventet å ferdigstilles i løpet av fjerde kvartal i år.

TekBot · desember 1, 2020, 7:06am

Disclosure of large shareholding

TekBot · desember 10, 2020, 7:00am

CARASENT ASA: APPROVED PROSPECTUS AND LISTING OF SHARES

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, SOUTH AFRICA, NEW ZEALAND, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

Oslo, December 10, 2020: Reference is made to the stock exchange announcement on 9 September 2020 where Carasent ASA (the “Company”) announced that the Company had carried out a successful private placement raising gross proceeds of approximately NOK 286 million (the “Private Placement”) through the placement of 12,190,146 new shares in the Company, each with a nominal value of NOK 1.332 and a subscription price of NOK 23.5 (the “Offer Shares”). Offer Shares corresponding to a number just below 20% of the outstanding share capital of the Company prior to the Private Placement was registered on the Company’s ordinary ISIN and listed upon issuance. The remaining portion of the Offer Shares (the “Unlisted Shares”) was registered on a separate ISIN and was unlisted pending approval of a listing prospectus (the “Prospectus”) by the Norwegian Financial Supervisory Authority (the “NFSA”). The NFSA has reviewed and approved the Company’s prospectus on December 9,2020 regarding the listing of Unlisted Shares. Following the NSFA approval of the Prospectus, the Unlisted Shares will be transferred to the Company’s ordinary ISIN and will be listed on the Oslo Stock Exchange.
…

Vis børsmeldingen

The Prospectus will be made available at:

www.carasent.com (hhtp://www.carasent.com)

The Prospectus will also be available at the offices of the Company.

For further information, please contact:

Johan Lindqvist, Chairman
johan.lindqvist@windchange.se
+46 733 55 09 35

Important Notices

This document is not an offer to sell or a solicitation of offers to purchase or subscribe for shares. Copies of this document may not be sent to jurisdictions, or distributed in or sent from jurisdictions, in which this is barred or prohibited by law. The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, in any jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction.

This communication may not be published, distributed or transmitted in or into the United States, Canada, Australia, the Hong Kong Special Administrative Region of the People’s Republic of China, South Africa or Japan and it does not constitute an offer or invitation to subscribe for or purchase any securities in such countries or in any other jurisdiction. In particular, the document and the information contained herein should not be distributed or otherwise transmitted into the United States of America or to U.S. persons (as defined in the U.S. Securities Act of 1933, as amended (the “Securities Act”)) or to publications with a general circulation in the United States of America. This document is not an offer for sale of securities in the United States. The securities referred to herein have not been and will not be registered under the Securities Act, or the laws of any state, and may not be offered or sold in the United States of America absent registration under or an exemption from registration under Securities Act. Carasent does not intend to register any part of the offering in the United States. There will be no public offering of the securities in the United States of America.
The information contained herein does not constitute an offer of securities to the public in the United Kingdom. No prospectus offering securities to the public will be published in the United Kingdom. This document is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

This announcement is an advertisement and does not constitute a prospectus for the purposes of the Prospectus Regulation (EU) 2017/1129 (as amended, together with any applicable implementing measures in any Member State, the “Prospectus Regulation”). In any EEA Member State that has implemented the Prospectus Regulation, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation.
Investing in securities involves certain risks.

This publication may contain specific forward-looking statements, e.g. statements including terms like “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions. Such forward -looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Carasent and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. Carasent assumes no responsibility to update forward -looking statements or to adapt them to future events or developments.

This announcement is made by and, and is the responsibility of, the Company.

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act and section 4-6 of the Oslo Rulebook II – Issuer Rules.

Kilde

TekBot · desember 10, 2020, 7:06am

Carasent ASA: Carasent ASA acquires Avans Soma AS

Press release
December 10, 2020

…

Vis børsmeldingen

Carasent ASA acquires Avans Soma AS

Carasent ASA has acquired the Norwegian company Avans Soma AS, developer of leading medical record systems and IT solutions in the Norwegian health care market.

We are very pleased to have completed this transaction as Avans Soma, with its strong presence in the Norwegian health care market, constitutes a foundation for our further establishment in Norway and other growth opportunities in new segments, says Johan Lindqvist, Chairman of the Board of Carasent.

Avans Soma is characterized by a large loyal customer base and stable market share growth during the last 15 years. This will provide a smooth access into the Norwegian health care market for Carasent.

– An existing organization in Norway, with the solid knowledge and experience that we see within Avans Soma, is extremely important. It creates great value, in terms of being able to use existing technical systems integrations and solutions that Avans Soma provides today. Through its robust organization of 25 highly competent employees, Avans Soma will also offer tangible guidance regarding sales, support and consulting in the Norwegian market, he says and continues:

– The wide range of contacts and business networks that Avans Soma developed over the past 15 years, in terms of customers and clients within the Norwegian healthcare market, private as well as public sector organizations, and partner relationships, represents an important strategic asset for the joint company. Avans Soma serves more than 140 customers, with a strong market share within the key segments.

The acquisition of Avans Soma and their products for social care and mental illness rehabilitation, results in a broadened product portfolio and the new collaboration enables Avans Soma to intensify its work towards offering SaaS-based services. Hence, there are strong organic growth opportunities both from the existing customer base and from winning new clients.

Avans Soma’s revenues and EBITDA was approximately NOK 24 million and NOK 6 million as per LTM Sep-2020, with an annually recurring revenue (“ARR”) of approx. NOK 21 million.

The agreed purchase price is NOK 122.5 million, corresponding to an enterprise value of NOK 125 million less Avans Soma’s consolidated net debt position of NOK 2.5 million (the (“Purchase Price”).

The transaction purchase price has been settled as follows:

50% of the Purchase Price in cash upon closing,

50% of the Purchase Price as shares in Carasent valued at a price of NOK 27.7 per share (the “Share Settlement”).

The majority shareholder of Avans Soma, Norwegian family office Rieber & Søn, will become a large shareholder in Carasent with approximately 2% of the outstanding shares following the transaction. All selling shareholders have entered into a lock-up agreement of 15 months on the Share Settlement.

DNB Markets acted as financial advisor to Carasent in connection with the transaction.

About the companies:

Carasent ASA:
Carasent ASA was founded in 1997. In May 2018 the Swedish company Evimeria EMR AB, a company providing cloud-based medical record services to the health care industry, was acquired. Carasent’s strategy is to develop and expand digitalization that helps customers in providing efficient and qualitative health care services in the Scandinavian market.

Avans Soma AS:
Avans Soma is a Norwegian company that develops and sells digital systems and tools adapted for users in the segments for health care, rehabilitation and mental illness. Avans Soma currently has 25 employees in offices in Oslo, Bergen and Dale.

For further information, please contact: Johan Lindqvist, Chairman Carasent ASA
Phone: +46 733 550935

Kilde

TekBot · desember 10, 2020, 7:10am

Carasent ASA: Changes in Board and Management

Anna Kinberg Batra proposed as new Board member of Carasent ASA
Dennis Höjer appointed as new CEO

…

Vis børsmeldingen

The Nomination Committee of Carasent ASA proposes that Anna Kinberg Batra be elected as new Board member at the extra Annual General Meeting on January 14, 2021. The Nomination Committee also proposes that Jesper Jannerberg, currently CEO and large shareholder, will be elected as new Board member.

Anna Kinberg Batra, 50, has extensive experience within politics and related business landscape in various segments. Previous positions include Leader of the Opposition and Leader of the Moderate Party from January 2015 to October 2017. She was also member of the Swedish parliament for Stockholm County from September 2006 to September 2018 and served as leader of the Moderate party in the parliament from 2010 to 2015. Her experience also includes local and regional office including the Stockholm region county council, its central board and its health and medical board. Anna Kinberg Batra is currently on the of Board of Collector AB, Svenska rymdaktiebolaget, SolTech Energy Sweden AB and SJR in Scandinavia AB.

Jesper Jannerberg, 51, today CEO of Carasent ASA, has worked for Carasent ASA and its subsidiary Evimeria EMR AB in different operational positions for more than 6 years. Jesper Jannerberg has long and extensive experience from the health care market as well as the IT cloud industry in general.

The proposal for election of the two new Board members was presented to the Nomination Committee by representatives of the company’s largest shareholders, who together represent approximately 40 percent of the outstanding shares and votes. The Nomination Committee has reviewed the proposal and also made consultation with other major shareholders. The proposal has obtained major support from all involved shareholders.

The Board of Directors of Carasent ASA announces that it has appointed Dennis Höjer as new CEO. Dennis is currently CEO of Evimeria EMR AB and COO of Carasent ASA and will assume his new position January 1st 2021.

“We are pleased to announce Dennis Höjer as new CEO of Carasent. We are confident that Dennis, with his strategic and performance-oriented skillset and solid track record in Evimeria EMR AB, has the skills and experience required to lead the company as it now enters into its next phase of growth”, says Johan Lindqvist, Chairman of the Board of Directors of Carasent.

Dennis Höjer, 33, is currently CEO of Evimeria EMR AB and COO of Carasent ASA, a position which he has held since 2018. Prior to 2018 Dennis had several different roles in Evimeria related to sales and marketing and he has been within the group since 2013.

“I am proud to be appointed CEO of Carasent, a company which I believe has the potential to be one of the market leaders in digitalization of the rapidly growing open care healthcare market. The primary focus going forward will be to make sure we continue to grow on our existing core markets in Sweden, but also to leverage acquisitions and organic initiatives in new geographies and segments. I look forward to the challenge and together with the team to take Carasent to even better performance”, says Dennis Höjer.

Jesper Jannerberg, CEO of Carasent ASA since May 2018, has decided to focus more on strategic tasks for Carasent. He remains a large shareholder and is proposed elected as Board member in Carasent ASA. In connection with the change Jesper comments:
“I am very satisfied with this change and are convinced Carasent with Dennis as new CEO, is well positioned for future growth.”

For further information, please contact:
Johan Lindqvist, Chairman of the Board of Directors
Phone: +46 733 550935

Kilde

winjard · desember 12, 2020, 5:45am

Synes dette virker som er meget god pris. I underkant av 6x ARR mot verdsettelsen av Carasent på omlag 25x ARR vil gi en god innvannende effekt.

Kjenner for lite til Avans Soma til å si noe om det strategiske her, utenom at det som sies i pressemeldingen om nettverk i Norge - 140 kunder og utvidet produktportefølje gir mening.

TekBot · desember 21, 2020, 1:09pm